20 assets in Mycobacterial Infectious Disease

Therapeutic assets addressing Mycobacterial Infectious Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Amoxicillin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Ansamycin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Azithromycin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Bedaquiline Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Cefoxitin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Ceftriaxone Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Clofazimine Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Doxycycline Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Ethambutol Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Imipenem Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Linezolid Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Moxifloxacin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Sulbactam Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Sulfamethoxazole Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Tigecycline Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Trimethoprim Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (53)
Cilastatin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (52)
Amikacin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (49)
Clarithromycin Mycobacterial Infectious Disease	The University of Queensland	P2	CCC (49)